Dr. Bissonnette is a drug discovery and development scientist with over 25 years of experience in oncology drug discovery and development, with particular emphasis and interest in immuno-oncology and translational medicine. He has extensive hands-on experience acting as PI on both preclinical (pharmacology) and nonclinical (safety) trials, focused on targeted oncology, immuno-oncology and inflammation therapeutics.… Continue reading Reid Bissonnette PhD
Dr. Olson is a biotechnology industry professional with broad scientific and operational experience, having a focus in process development, manufacturing and other CMC related activities for many clinical and commercial products. With over forty years of experience, he is a true veteran, having enabled the production of virtually every class and size of biological product… Continue reading Chuck Olson, PhD
Paul is a seasoned CEO with over two decades of experience in biologics and small-molecule research and development. He has successfully commercialized products in infectious diseases, immunology, and oncology. With senior management roles at renowned companies, Paul brings strategic expertise to his current positions as executive chairman of Cardea Bio and board member at Amplyx… Continue reading Paul Grint, MD
Lynnet Koh is a serially successful, award-winning entrepreneur who founded Targazyme with the commitment to transform cancer treatment with innovative cancer immunotherapies aimed at curing cancer without the toxic side effects of standard-of-care cancer therapies. Under her leadership, the company has achieved significant milestones, including the development of potential mega blockbuster Phase 3 ready drug… Continue reading Lynnet Koh, MS, MBA
